<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070434</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000334469</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0304</secondary_id>
    <nct_id>NCT00070434</nct_id>
  </id_info>
  <brief_title>S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum</brief_title>
  <official_title>A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, leucovorin, fluorouracil, and&#xD;
      oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation&#xD;
      therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well different regimens of induction&#xD;
      chemotherapy followed by chemoradiotherapy work in treating patients with locally advanced&#xD;
      adenocarcinoma of the rectum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of obtaining a pre-treatment determination of intratumoral&#xD;
           molecular markers (TS, DPD, and ERCC-1) for use in selection of the appropriate regimen&#xD;
           for induction cytotoxic combination chemotherapy in patients with cT3-4 rectal&#xD;
           adenocarcinoma.&#xD;
&#xD;
        -  Determine the response probability (unconfirmed, complete and partial) in patients&#xD;
           treated with targeted induction cytotoxic chemotherapy.&#xD;
&#xD;
        -  Determine the toxicity of targeted induction cytotoxic chemotherapy and&#xD;
           chemoradiotherapy in these patients.&#xD;
&#xD;
        -  Determine the response probability in these patients treated with chemoradiotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction chemotherapy: Patients are assigned to 1 of 3 treatment groups based on&#xD;
           molecular analysis of the pretreatment tumor specimen.&#xD;
&#xD;
             -  Group I (lower likelihood of resistance to a fluorouracil-based regimen): Patients&#xD;
                receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours on day&#xD;
                1 and fluorouracil IV over 46 hours beginning on day 1.&#xD;
&#xD;
             -  Group II (higher likelihood of resistance to a fluorouracil-based regimen):&#xD;
                Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on&#xD;
                day 1.&#xD;
&#xD;
             -  Group III (high likelihood of sensitivity to oxaliplatin and fluorouracil therapy):&#xD;
                Patients receive oxaliplatin IV over 90 minutes and leucovorin calcium IV over 2&#xD;
                hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.&#xD;
&#xD;
      Treatment in all groups repeats every 2 weeks for 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are evaluated for response approximately 2 weeks after the completion of induction&#xD;
      chemotherapy. Patients with stable disease or better receive chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning approximately 3 weeks after the completion of induction&#xD;
           chemotherapy, patients receive oral capecitabine twice daily continuously for 5 weeks&#xD;
           and concurrent radiotherapy once daily 5 days a week for 5 weeks.&#xD;
&#xD;
      After chemoradiotherapy, patients may undergo attempted surgical resection at the discretion&#xD;
      of the treating physician.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-65 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response (confirmed and unconfirmed response, complete response, partial response)</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>825mg/m2 BID, PO, daily</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Bolus + IV for 46 hrs on Day 1</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>IV infusion over 90 min on Day 1</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>200mg/m2 IV 2 hour infusion on Day 1</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>85mg/m2 IV infusion for 90minutes on Day 1</description>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>50mg TID, PO daily</description>
    <arm_group_label>Irinotecan + 5-FU + Leucovorin</arm_group_label>
    <arm_group_label>Irinotecan + Oxaliplatin</arm_group_label>
    <arm_group_label>Oxaliplatin + 5-FU + Leucovorin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary adenocarcinoma of the rectum&#xD;
&#xD;
          -  Locally advanced disease (clinical T3-4, N0-2, M0) based on at least 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Clinically fixed tumors on rectal examination with tumor adherent to the pelvic&#xD;
                  sidewall and/or sacrum&#xD;
&#xD;
               -  Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the lack&#xD;
                  of clear tissue plane is considered evidence of fixation&#xD;
&#xD;
               -  Hydronephrosis on CT scan or intravenous pyelogram of ureteric or bladder&#xD;
                  invasion by cystoscopy and cytology or biopsy&#xD;
&#xD;
               -  Invasion into the prostate, vagina, or uterus&#xD;
&#xD;
          -  Transmural penetration of tumor through the muscularis propria as evidenced by CT scan&#xD;
             or MRI and endorectal ultrasound&#xD;
&#xD;
          -  Distal border of the tumor must be at or below the peritoneal reflection (within 12 cm&#xD;
             of the anal verge) by proctoscopic examination&#xD;
&#xD;
          -  Measurable disease by x-ray, scans, or physical examination&#xD;
&#xD;
          -  Available tumor tissue to determine molecular profile of the tumor before study&#xD;
             treatment&#xD;
&#xD;
          -  No clinical evidence of high-grade (lumen diameter &lt; 1 cm) large bowel obstruction&#xD;
             unless a diverting colostomy has been performed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Estimated creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
          -  No recent myocardial infarction&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior unanticipated severe reaction to study drugs&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No serious uncontrolled infection&#xD;
&#xD;
          -  No other serious medical illness that would preclude study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for colon or rectal cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No prior intra-operative radiotherapy or brachytherapy&#xD;
&#xD;
          -  No concurrent intra-operative radiotherapy or brachytherapy&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles R. Thomas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heinz-Josef Lenz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert P. Whitehead, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James L. Abbruzzese, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen R. Smalley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiation Oncology Center of Olathe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morton S. Kahlenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

